Current Keytruda Discounts for Patients
Keytruda (pembrolizumab), made by Merck, costs around $11,000 per dose without insurance, but discounts exist through manufacturer programs. Merck's Keytruda Savings Card cuts out-of-pocket costs to $0 for eligible commercially insured patients, covering up to 16 doses per year (about $150,000 in product value). Patients qualify if they have private insurance, no government coverage like Medicare, and household income under $100,000 (varies by plan). Apply at Merck's patient assistance site or call 1-855-257-3932.[1]
Uninsured or underinsured patients can access Keytruda for free via Merck's Patient Assistance Program if income is below 400% of the federal poverty level (e.g., $58,320 for one person in 2024). No citizenship requirement, but U.S. residency needed.[1]
Medicare and Government Coverage Options
Medicare Part D covers Keytruda, but high costs trigger the Inflation Reduction Act's $2,000 out-of-pocket cap starting 2025. For 2024, low-income subsidy (LIS) patients pay little to nothing. Check eligibility via Medicare.gov or SHIP counselors.[2]
Medicaid and VA programs often cover it fully for eligible patients.
Pharmacy and Third-Party Discounts
GoodRx coupons lower cash prices to $8,500-$10,000 per dose at pharmacies like Walmart or CVS, though still high. SingleCare offers similar savings up to 80% off list price, but less effective for insured patients.[3]
Amazon Pharmacy provides Keytruda with free shipping for Prime members, sometimes bundled with savings cards.
How to Maximize Savings on Keytruda
Combine options: Use the Merck card first, then GoodRx for residuals. Patient Access Network (PAN) Foundation grants up to $10,800 yearly for copays if income is 400-500% of poverty level.[4] HealthWell Foundation covers additional gaps.
| Program | Eligibility | Savings |
|---------|-------------|---------|
| Merck Savings Card | Commercial insurance, income limits | $0 copay up to 16 doses |
| Merck PAP | Uninsured/low-income | Free drug |
| GoodRx/SingleCare | Cash pay | 20-30% off retail |
| PAN Foundation | Copay assistance | Up to $10,800/year |
Consult a doctor or social worker for personalized help; eligibility changes yearly.
Keytruda Patent Status and Future Pricing
Merck holds patents on Keytruda until 2028 (U.S. Patent 8,952,138) with pediatric exclusivity to 2034, delaying generics.5 No biosimilars yet, but challenges from Amgen and others could lower prices post-2028. Track updates on DrugPatentWatch.com.5
Sources
[1]: merckhelps.com/keytruda
[2]: medicare.gov
[3]: goodrx.com/keytruda
[4]: panfoundation.org